S

    Sionna Therapeutics, Inc. Common Stock (SION)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.03
    +0.16 (+2.73%)

    Market Cap: $272.26M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(3/7)
    Avg Surprise
    -4.48%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.67
    Range$-0.86 - $-0.56
    8 analysts
    EPS Revisions
    1
    0
    7d
    1
    3
    30d
    EPS Estimate Drift
    90d ago$-0.70-4.5%
    60d ago$-0.65+3.4%
    30d ago$-0.65+3.4%
    7d ago$-0.65+3.4%
    Current$-0.67
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.75
    Range$-1.36 - $-0.50
    9 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.75---
    Sep 26EST
    		-$-0.67---
    Jun 26
    Reported Aug 6
    		$-0.66$-0.64-3.13%Miss-61.0%
    Mar 26
    Reported May 12
    		$-0.60$-0.50-20.00%Miss+3.2%
    Dec 25
    Reported Mar 2
    		$-0.46$-0.71+35.21%Beat+86.4%
    Sep 25
    Reported Nov 5
    		$-0.46$-0.52+11.54%Beat-
    Jun 25
    Reported Aug 11
    		$-0.41$-0.45+8.89%Beat-
    Mar 25
    Reported May 12
    		$-0.62$-0.45-37.78%Miss-
    Dec 24
    Reported Mar 20
    		$-3.38$-2.68-26.12%Miss-

    Key Metrics

    Valuation
    P/E Ratio-2.77EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-32.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio20.05xQuick Ratio20.05x
    Trading Statistics
    BetaN/AAvg Volume4.40M
    52-Week High$54.9752-Week Low$4.01

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.90
    SMA 20$14.58
    SMA 50$32.49
    SMA 200$37.74
    EMA 10$7.65
    EMA 20$14.15
    EMA 50$26.01
    EMA 200$33.47

    MACD

    Line: -8.78Signal: -9.21Hist: 0.43

    ADX

    ADX: 48.3+DI: 14.5-DI: 48.3

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down40.0
    PSAR$41.65

    Bollinger Bands

    Upper Band$50.42
    Lower Band$-21.26
    %B Position49154%(Upper)
    Band Width0.38

    RSI (14-Day)

    Oversold
    24.0

    Momentum Oscillators

    Stoch %K63.7
    Stoch %D45.6
    Williams %R-42.2
    ROC (10d)2.0%
    Momentum0.12
    CCI (20d)-41.1
    MFI (14d)63.6

    Volatility Measures

    ATR (14d)$2.55(42.2%)
    StdDev (20d)17.92
    Hist Vol352.9%(High)

    Volume Flow

    VWAP$5.95
    OBV5.0M
    AD Line16.4M
    CMF (20d)0.145

    Volume Metrics

    Avg Vol (20d)4.6M
    Vol Ratio0.3x(Low)
    VWMA (20d)$6.80

    Pivot Points

    R3$6.25
    R2$6.16
    R1$6.01
    Pivot Point$5.92
    S1$5.77
    S2$5.68
    S3$5.54

    Advanced Oscillators

    TSI-52.25
    Ultimate Osc55.1
    KST-791.36

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$152,000$0$0$0N/A$0$0$0N/A
    Gross Profit$0$0$-152,000$0$0$0N/A$0$0$0N/A
    Operating Expenses$32.47M$29.60M$23.61M$23.80M$21.73M$19.66M$18.13M$27.98M$11.29M$13.15M$12.60M
    R&D$21.86M$18.96M$15.17M$16.04M$15.38M$13.67M$14.25M$24.58M$8.23M$10.22M$9.89M
    SG&A$10.61M$10.64M$8.44M$7.76M$6.52M$5.99M$3.88M$3.40M$3.06M$2.93M$2.71M
    Operating Income$-32,470,000$-29,599,000$-23,612,000$-23,805,000$-21,906,000$-19,659,000$-18,133,000$-27,984,000$-11,292,000$-13,147,000$-12,595,000
    Interest Income$2.59M$2.82M$3.17M$3.46M$3.67M$3.00M$2.12M$2.35M$2.57M$1.13M$553,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-29,883,000$-26,779,000$-20,859,000$-20,278,000$-18,239,000$-16,482,000$-15,848,000$-25,441,000$-8,552,000$-11,847,000$-11,876,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-29,886,000$-26,779,000$-20,440,000$-20,278,000$-18,068,000$-16,482,000$-15,848,000$-25,441,000$-8,552,000$-11,847,000$-11,876,000
    EBITDA$-32,472,000$-29,645,000$-23,813,000$-24,381,000$-23,416,000$-19,529,000$-18,590,000$-28,622,000$-12,055,000$-12,924,000$-11,715,000
    EBIT$-32,470,000$-29,599,000$-23,612,000$-23,734,000$-21,906,000$-19,482,000$-17,967,000$-27,794,000$-11,118,000$-12,979,000$-11,876,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SION

    News

    Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

    Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Sionna Therapeutics, Inc. (NASDAQ: SION) following a significant drop in its stock price. This comes after Sionna reported disappointing topline data from its PreciSION CF Phase 2a trial and announced it would not advance SION-719. The firm is encouraging shareholders who purchased Sionna securities to contact them to learn more about potential claims.

    The National Law Review•8/26/26•
    Bearish

    Robbins LLP Reminds Investors it is Investigating Sionna Therapeutics for Potential Securities Violations

    Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) for potential securities violations and breaches of fiduciary duties after its stock plunged 92% following disappointing Phase 2a clinical trial results for SION-719 in cystic fibrosis. The trial failed to meet its primary endpoint, leading the company to consider capital preservation measures. Shareholders who lost money are encouraged to contact Robbins LLP for more information.

    GlobeNewswire•8/25/26•
    Neutral

    Securities Fraud Investigation Into Sionna Therapeutics,

    The Law Offices of Frank R. Cruz is continuing its investigation into Sionna Therapeutics, Inc. (SION) regarding potential violations of federal securities laws after the company announced a primary endpoint miss in its PreciSION CF Phase 2a trial. This news led to a 91.2% stock drop, injuring investors. Shareholders who lost money are encouraged to contact the firm to potentially pursue a claim.

    GlobeNewswire•8/25/26•
    Neutral

    SION Forecast — Price Target — Prediction for 2027

    This article provides a forecast and price target for Sionna Therapeutics, Inc. (SION), based on analyst opinions. It details maximum and minimum price estimates, upcoming earnings reports, historical financial data such as EPS, revenue, and net income, and confirms that SION does not pay dividends.

    TradingView•8/25/26•
    Somewhat-Bullish

    Raymond James Initiates Sionna Therapeutics(SION.US) With Hold Rating

    Raymond James has initiated coverage on Sionna Therapeutics (SION.US) with a Hold rating. This indicates a neutral stance on the stock by the brokerage firm.

    Moomoo•8/24/26•
    Neutral

    Frequently Asked Questions About SION

    Does SION pay dividends?
    Sionna Therapeutics, Inc. Common Stock (SION) does not currently pay a regular dividend.
    What is SION's market cap?
    Sionna Therapeutics, Inc. Common Stock (SION) has a market capitalization of $272.26M with a current stock price of $6.03.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In